DEV ENVIRONMENT — Not Production

MSc Cancer Immunotherapy

  • Postgraduate
  • London
MSc Cancer Immunotherapy
London Metropolitan University

Course Overview

Intake

January 2027

Duration

1 year

Course Description

This master's course is designed for students looking to advance their knowledge in the rapidly evolving field of cancer treatment. Drawing on expertise from the institution's Cellular and Molecular Immunology Research Centre, the programme provides an in-depth understanding of molecular targets, drug therapies, and the role of the immune system in cancer development. Students will explore topics such as monoclonal antibodies, DNA vaccines, and immuno-chemotherapy, while developing essential practical skills in data collection and analysis. The course is available on a full-time basis (1 year) or part-time (2 years), making it suitable for those balancing professional commitments. By the end of the programme, students will be well-prepared for careers in industry, academia, or the NHS, equipped with the intellectual and practical tools to tackle the global challenge of cancer. The institution encourages students to engage with professional societies to enhance their CVs and build valuable networks within the scientific community.

Tuition Fee Details

The tuition fee for UK home students is £11,000 per year for full-time study. For part-time study, the fee is £1,225 per 20-credit module. The university reserves the right to increase the tuition fees in line with changes to legislation, regulation and any government guidance or decisions. More information on the latest fee can be found on the institution website.

Course Structure

Advanced Immunology

20 Credits

Cancer Immunotherapy

20 Credits

Cancer: Diagnosis and Therapy

20 Credits

Fundamentals of Medical Genetics and Genomics

20 Credits

Molecular Oncology

20 Credits

Research Project

60 Credits

Scientific Frameworks For Research

20 Credits

Frequently Asked Questions

Graduates are well-prepared for roles in biopharmaceutical companies, academic research, and the NHS, with opportunities to work on developing innovative cancer immunotherapies.